|
1
|
Protective conditioning for acute graft-versus-host disease.
|
N Engl J Med
|
2005
|
4.07
|
|
2
|
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
|
JAMA
|
2011
|
3.45
|
|
3
|
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial.
|
Blood
|
2002
|
3.05
|
|
4
|
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
|
J Clin Oncol
|
2008
|
2.99
|
|
5
|
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.
|
Blood
|
2002
|
2.49
|
|
6
|
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
|
Blood
|
2007
|
2.49
|
|
7
|
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.
|
Blood
|
2003
|
2.33
|
|
8
|
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
|
Blood
|
2004
|
2.18
|
|
9
|
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2008
|
2.15
|
|
10
|
Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2005
|
2.12
|
|
11
|
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
|
J Clin Oncol
|
2005
|
2.04
|
|
12
|
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.
|
Blood
|
2009
|
1.89
|
|
13
|
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
|
Biol Blood Marrow Transplant
|
2008
|
1.75
|
|
14
|
A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.
|
Biol Blood Marrow Transplant
|
2006
|
1.58
|
|
15
|
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
|
Blood
|
2003
|
1.55
|
|
16
|
Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
|
Biol Blood Marrow Transplant
|
2006
|
1.54
|
|
17
|
Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells.
|
Biol Blood Marrow Transplant
|
2011
|
1.49
|
|
18
|
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.
|
Biol Blood Marrow Transplant
|
2002
|
1.46
|
|
19
|
Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
|
Blood
|
2003
|
1.35
|
|
20
|
Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen.
|
Blood
|
2008
|
1.33
|
|
21
|
Patients beware: commercialized stem cell treatments on the web.
|
Cell Stem Cell
|
2010
|
1.32
|
|
22
|
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2005
|
1.23
|
|
23
|
Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation.
|
Br J Haematol
|
2005
|
1.18
|
|
24
|
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2005
|
1.10
|
|
25
|
Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients.
|
Blood
|
2002
|
1.07
|
|
26
|
Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: a 15-year experience.
|
Exp Hematol
|
2003
|
0.97
|
|
27
|
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2006
|
0.93
|
|
28
|
Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
|
Int J Hematol
|
2002
|
0.89
|
|
29
|
Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2010
|
0.86
|
|
30
|
Acute renal failure after nonmyeloablative hematopoietic cell transplantation.
|
J Am Soc Nephrol
|
2004
|
0.85
|
|
31
|
Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives.
|
J Clin Immunol
|
2002
|
0.80
|
|
32
|
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
|
Biol Blood Marrow Transplant
|
2003
|
0.78
|
|
33
|
Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
|
Biol Blood Marrow Transplant
|
2003
|
0.77
|
|
34
|
A rare combination of two inherited disorders in one patient: pyruvate kinase deficiency and hemochromatosis.
|
Ann Hematol
|
2009
|
0.76
|
|
35
|
A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
|
Biol Blood Marrow Transplant
|
2004
|
0.75
|